医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer

2015年10月20日 AM01:00
このエントリーをはてなブックマークに追加


 

SANTA ANA, Calif.

Cold Genesys, Inc., a late-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) accepted a Phase I/II Clinical Trial (NAOMI) using CG0070 plus an anti-CTLA-4 checkpoint inhibitor as a neo-adjuvant immunotherapy for muscle invasive bladder cancer, or MIBC. CG0070 is an oncolytic adenovirus expressing GM-CSF designed to selectively replicate in tumors.

This Phase I/II NAOMI trial is planned to evaluate the safety and efficacy of the neo-adjuvant combination of CG0070 plus anti-CTLA-4 in patients with MIBC who are ineligible for platinum-based chemotherapy. One of the primary endpoints is to evaluate the efficacy of this intervention to increase the expression of PD-L1 in the primary tumor.

“Based on our encouraging results in non-muscle invasive bladder cancer (NMIBC), we are excited to begin investigating this product in muscle invasive bladder cancer (MIBC),” said Alex Yeung, MBBS, CEO and Chairman of Cold Genesys. “This is an important milestone for Cold Genesys as positive results in this trial can theoretically increase the chance to further use an anti-PD1 or anti-PD-L1 blocker as an adjuvant in MIBC patients, who usually are deficient in PD-L1 and prone to disease recurrence. The rapid enrollment in our pivotal trial for BCG-failure NMIBC or the BOND II trial is also promising. To fulfill the requirements by the FDA in granting us the Pivotal BOND II trial, we have also initiated our new manufacturing and quality control processes, targeted for completion in the 2Q 2016.”

About CG0070

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold virus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 was designed to work in two important and complementary ways. First, it replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. The scientific rationale and clinical profile of CG0070 makes it an ideal agent to be developed for a variety of solid tumor types in combination with immune checkpoint modulators.

About Cold Genesys, Inc.

Cold Genesys, Inc. is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. In 2010, Cold Genesys acquired exclusive worldwide rights to develop CG0070 from BioSante Pharmaceuticals. CG0070 is currently under investigation in a Phase II, single-arm, open-label, pivotal study (BOND II) for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have failed BCG therapy and refused cystectomy. In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators in different solid tumors.

For more information, please visit: www.coldgenesys.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151019005504/en/

CONTACT

Cold Genesys, Inc.
Sharon Hsu
Public Relations
sharon.hsu@coldgenesys.com
or
Arthur
Kuan
Chief Operating Officer
arthur.kuan@coldgenesys.com
714-884-3953

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表